Cyclacel Pharmaceuticals to Present at the 32nd Annual Oppenheimer Healthcare Conference
March 09, 2022 07:00 ET
|
Cyclacel
BERKELEY HEIGHTS, N.J., March 09, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing...
Cyclacel Pharmaceuticals to Participate in 2022 BIO CEO & Investor Conference
February 07, 2022 07:00 ET
|
Cyclacel
BERKELEY HEIGHTS, N.J., Feb. 07, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative...
Cyclacel Pharmaceuticals Reviews 2021 Achievements And Announces Key Business Objectives for 2022
January 06, 2022 07:00 ET
|
Cyclacel
– Now Enrolling Patients in Two Registration-Directed Trials for Lead Candidate, Oral Fadraciclib – – Expecting Key Data Readouts for Oral Fadraciclib in 2022 – – Planning to Launch...
Cyclacel Pharmaceuticals to Participate in Biotech Showcase 2022 Virtual Conference
December 23, 2021 07:00 ET
|
Cyclacel
BERKELEY HEIGHTS, N.J., Dec. 23, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative...
Cyclacel Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Business Update
November 10, 2021 16:05 ET
|
Cyclacel
- Second Phase 1/2 Study of Fadraciclib Now Enrolling Patients in Leukemia -- Cash Runway to Early 2023 -- Conference Call Scheduled November 10, 2021 at 4:30 p.m. ET - BERKELEY HEIGHTS, N.J., Nov. ...
Cyclacel Announces Dosing of First Patient in Phase 1/2 Study of Oral Fadraciclib in Patients With Leukemias or Myelodysplastic Syndromes
November 05, 2021 09:41 ET
|
Cyclacel
BERKELEY HEIGHTS, N.J., Nov. 05, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative...
Cyclacel Pharmaceuticals to Release Third Quarter 2021 Financial Results and Provide Business Update
October 29, 2021 07:00 ET
|
Cyclacel
BERKELEY HEIGHTS, N.J., Oct. 29, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative...
Cyclacel Pharmaceuticals Presenting at Three Conferences in September
September 08, 2021 07:00 ET
|
Cyclacel
BERKELEY HEIGHTS, N.J., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing...
Cyclacel Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Business Update
August 11, 2021 16:05 ET
|
Cyclacel
- Announces First Patients with Solid Tumors Dosed with Oral Fadraciclib -- Additional Phase 1/2 Trials for Fadraciclib and CYC140 Expected to Follow -- Cash Runway to Early 2023 -- Conference Call...
Cyclacel Pharmaceuticals to Release Second Quarter 2021 Financial Results and Provide Business Update
August 03, 2021 07:00 ET
|
Cyclacel
BERKELEY HEIGHTS, N.J., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative...